Spread the love

A recent study from the From the Department of Surgery, University of Pittsburgh Cancer Institute, Division of Pediatric Surgery, Children’s Hospital Pittsburgh, Department of Pharmacology and Chemical Biology, and Vascular Medicine Institute, University of Pittsburgh School of Medicine, PA, USA shows that “Genetic deletion of toll-like receptor 4 on platelets attenuates experimental pulmonary hypertension.” This study was published in the 9 May 2014 issue of the Journal “Circulation Research” [I.F:>10.00] by Drs. Bauer PMBauer EM and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for pulmonary hypertension: MiRNA-100-5p stifles pulmonary hypertension via down regulation of its target gene. This study suggests, for the first time, that MiRNA-100-5p, by decreasing the expression of its target gene, may decrease: (1) Right ventricular systolic pressure, (2) Right ventricular hypertrophy, and (3) pulmonary vascular remodeling. Together, pharmacological formulations encompassing “MiRNA-100-5p activators” may be used to treat patients suffering from pulmonary hypertension.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan,  MiRNA-based therapy for pulmonary hypertension: MiRNA-100-5p stifles pulmonary hypertension via down regulation of its target gene, 16/March/2015,  12.31 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How MiRNA-100-5p stifles pulmonary hypertension

Spread the love